In the following video, Motley Fool health care bureau chief Brenton Flynn discusses an upcoming FDA decision on this Sunday, Feb. 10, on whether to approve Celgene's (NASDAQ:CELG) drug pomalidomide, which is used in the treatment of blood cancer multiple myeloma. While there is little doubt that the drug will be approved, Brenton highlights the bigger question at stake here: Considering the competition in this space -- including one of Celgene's own drugs, which may cannibalize sales -- just how big will this drug become?
Motley Fool Returns
Discounted offers are only available to new members. Stock Advisor will renew at the then current list price. Stock Advisor list price is $199 per year.
Stock Advisor launched in February of 2002. Returns as of 10/19/2021.
Average returns of all recommendations since inception. Cost basis and return based on previous market day close.